Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
9 studies found for:    18650514 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib
Condition: Hepatocellular Carcinoma
Intervention: Procedure: blood sample collection
2 Not yet recruiting Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Other: control;   Drug: sorafenib;   Drug: aspirin
3 Recruiting Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Adjuvant chemotherapy;   Procedure: Follow-up
4 Not yet recruiting Adjuvant Therapies for Patients With HCC and MVI
Condition: Hepatocellular Carcinoma
Interventions: Procedure: TACE;   Drug: Sorafenib;   Drug: TACE plus sorafenib;   Procedure: transarterial chemotherapy plus embolization
5 Recruiting Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)
Conditions: Hepatocellular Carcinoma;   Metastasis
Interventions: Procedure: Conventional Transarterial Chemoembolization (TACE);   Drug: sorafenib
6 Active, not recruiting Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hcc
Condition: Advanced Hepatocellular Carcinoma
Intervention: Drug: Immuncell-LC
7 Completed
Has Results
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Conditions: Hepatocellular Carcinoma;   Hepatocellular Cancer;   Carcinoma, Hepatocellular
Intervention: Drug: TRC105
8 Active, not recruiting Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
Conditions: Hepatocellular Carcinoma;   CHILD B
Interventions: Drug: sorafenib;   Drug: Pravastatin;   Drug: Sorafenib + Pravastatin;   Other: patients receiving best supportive care
9 Completed
Has Results
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo

Indicates status has not been verified in more than two years